Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

Phase 3

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: temsirolimus (Torisel)
Drug: Sorafenib

Registration Number: NCT00474786

Lead Sponsor: Pfizer

Brief Summary: This is an international, randomized, open-label, outpatient, multicenter study. Subjects will be assigned in a 1:1 ratio to 1 of 2 treatment arms: temsirolimus 25 mg once weekly by intravenous (IV) infusion or sorafenib 400 mg by mouth (PO) twice daily (BID). These investigational drugs will be administered in 6-week cycles for the duration of the study, up to 24 months. Subjects will be stratified by nephrectomy status, duration of response to sunitinib therapy, Memorial Sloan Kettering Cancer Center (MSKCC) prognostic group, and RCC tumor histology.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 512

Inclusion Criteria

Histologically confirmed diagnosis of mRCC (regardless of histology or nephrectomy status) with well-documented Radiological PD by RECIST criteria or clinical PD as judged by the investigator while receiving first-line sunitinib therapy. Subjects must have at least 1 cycle of sunitinib therapy (minimum of four weeks continuously).
At time of randomization, at least 2 weeks since prior treatment with sunitinib, palliative radiation therapy, and/or surgery.
At time of randomization, there must be at least 1 measurable lesion per RECIST. Lesions that have been previously irradiated or embolized cannot be selected as target lesions.
- More criteria apply

Exclusion Criteria

Metastatic CNS from RCC.
Subjects who discontinued Sutent therapy due specifically to intolerance.
Prior systemic therapy for mRCC other than sunitinib.
Active ketonuria, secondary to poorly controlled diabetes mellitus
- More criteria apply

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
2	temsirolimus (Torisel)	-
1	Sorafenib	-

Primary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS)	Baseline up to 24 Months	Interval from date of randomization until documentation of progressive disease (PD) by an independent tumor assessment according to Response Evaluation Criteria in Solid Tumor (RECIST) or death for any reason whichever occurred first.

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival (PFS) by Investigator Assessment	Baseline up to 24 Months	Interval from date of randomization until documentation of PD by an investigator tumor assessment, symptomatic deterioration, or death for any reason whichever occurred first.
Overall Survival (OS)	Baseline to date of death from any cause (up to 24 months)	Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.
Percentage of Participants With PFS Events at 12, 24 and 36 Weeks by Independent Assessment	Weeks 12, 24, and 36	PFS: Interval from date of randomization until documentation of PD by an independent tumor assessment according to RECIST or death for any reason whichever occurred first. PFS calculated as (Weeks)=(randomization date minus first dose date plus 1) divided by 7.
Percentage of Participants With Tumor Response	Baseline up to 24 Months	Percentage of participants with tumor response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST and evaluated by independent central review. CR/PR persisted on repeat imaging study at least 4 weeks after initial documentation of response. PR had at least 30 percent decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.
Duration of Response (DR)	Baseline up to 24 Months	Duration of response as defined by the time from CR or PR (whichever status recorded first) until the date of death or PD was objectively documented. Median and its 95 percent confidence interval (95% CI) were estimated using Kaplan-Meier method.